Back to News
Oct 17, 2025 4:00 PM

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).

The data demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months).

Results showed a 28.4% reduction in risk of recurrence in patients with high-risk stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early ...